177 related articles for article (PubMed ID: 36268880)
1. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
[TBL] [Abstract][Full Text] [Related]
2. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
3. Peptide-Based
De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
[TBL] [Abstract][Full Text] [Related]
4. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
[TBL] [Abstract][Full Text] [Related]
5. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
6. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model.
Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H
Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912
[TBL] [Abstract][Full Text] [Related]
9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
10. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
11. Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.
Jouini N; Cardinale J; Mindt TL
ChemMedChem; 2022 Jun; 17(12):e202200091. PubMed ID: 35388635
[TBL] [Abstract][Full Text] [Related]
12. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143
[TBL] [Abstract][Full Text] [Related]
13. Construction of Anti-hPD-L1 HCAb Nb6 and
Huang HF; Zhu H; Li GH; Xie Q; Yang XT; Xu XX; Tian XB; Wan YK; Yang Z
Bioconjug Chem; 2019 Oct; 30(10):2614-2623. PubMed ID: 31535847
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
[TBL] [Abstract][Full Text] [Related]
15. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
17. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
18. Development of [
Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
[TBL] [Abstract][Full Text] [Related]
19. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
[TBL] [Abstract][Full Text] [Related]
20. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]